 |
|
Michael R. Bristow, MD, Ph.D.CEO and Chief Science and Medical OfficerDr. Bristow joined ARCA as one of ARCA’s founders in September 2004, and has served as Chairman and Chief Science and Medical Officer of ARCA until he was appointed to his current position of Chief Executive Officer in July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen’s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006.
Jean-François Formela, MDDirectorDr. Formela has served as a member of ARCA's board of directors since February 2006. Jean-François Formela is a Partner in the Life Sciences group focused on biopharmaceuticals. He joined Atlas Venture in 1993 to build the US life sciences franchise. Previously, Jean-Francois was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the US. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, he directed the US Phase IV studies in all therapeutic areas, as well as the health economics and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University Hospital in Paris. Since joining Atlas Venture, Jean-François has been involved in the formation of companies such as Adnexus, Archemix, ArQule (NASDAQ: ARQL), Aureon Laboratories, Cellzome, deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP). He was also an investor in Achillion (NASDAQ: ACHN) and Nuvelo (NASDAQ: NUVO) and director of biochem pharma and Novexel. He currently serves on the Boards of Atlas portfolio companies ARCA biopharma, Cellzome, Egalet, Horizon Pharma, Resolvyx and f-star. Linda Grais, MDLead Independent Director
Dr. Grais has served as a member of ARCA’s board of directors since May 2007. She is a former Partner at Interwest Partners. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School.
John L. Zabriskie, Ph.D. Director
Dr. Zabriskie has served as a member of ARCA’s board of directors since March 2005. Dr. Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief Executive Officer and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products in July 1997, Dr. Zabriskie was President and Chief Executive Officer of Pharmacia and Upjohn Inc. Prior to joining Upjohn in 1994, Dr. Zabriskie was Executive Vice President for Merck & Co., Inc. He currently serves on the board of directors of Array BioPharma Inc., Kellogg Co. and Protein Forest Inc. Dr. Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his Ph.D. in organic chemistry from the University of Rochester.
|
|
|
|
